Home » Stocks » RVNC

Revance Therapeutics, Inc. (RVNC)

Stock Price: $27.43 USD -1.05 (-3.69%)
Updated May 10, 2021 4:00 PM EDT - Market closed
Market Cap 2.01B
Revenue (ttm) 15.33M
Net Income (ttm) -282.09M
Shares Out 58.01M
EPS (ttm) -4.86
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day May 10
Last Price $27.43
Previous Close $28.48
Change ($) -1.05
Change (%) -3.69%
Day's Open 28.14
Day's Range 27.43 - 28.56
Day's Volume 305,750
52-Week Range 18.39 - 34.62

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

Shares of Revance Therapeutics (NASDAQ:RVNC) were flat in after-market trading after the company reported Q1 results. Quarterly Results Earnings per share increased 6.09% over the past year to ($1.08), ...

13 hours ago - Benzinga

NASHVILLE, Tenn.--(BUSINESS WIRE)--Revance Reports First Quarter 2021 Financial Results, Provides Corporate Update

14 hours ago - Business Wire

NASHVILLE, Tenn.--(BUSINESS WIRE)--Revance to Release First Quarter 2021 Financial Results on Monday, May 10, 2021

1 week ago - Business Wire

Revance Therapeutics, Inc. (RVNC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

1 week ago - Zacks Investment Research

NASHVILLE, Tenn.--(BUSINESS WIRE)--Revance to Share Data at The Aesthetic Meeting 2021 that Supports DaxibotulinumtoxinA's 24-Week Duration Profile Across Multiple Female Age Cohorts

1 week ago - Business Wire

NASHVILLE, Tenn.--(BUSINESS WIRE)--Revance Announces First Patient Enrolled for DaxibotulinumtoxinA in Glabellar Lines and Cervical Dystonia in China by Fosun Pharma

1 week ago - Business Wire

NASHVILLE, Tenn.--(BUSINESS WIRE)--Revance to Participate in the 20th Annual Needham Virtual Healthcare Conference

1 month ago - Business Wire

NASHVILLE, Tenn.--(BUSINESS WIRE)--Revance to Showcase Phase 3 Results Evaluating DaxibotulinumtoxinA for Injection for the Treatment of Cervical Dystonia at AAN Annual 2021 Meeting

1 month ago - Business Wire

Revance Therapeutics, Inc. (RVNC) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the n...

1 month ago - Zacks Investment Research

NASHVILLE, Tenn.--(BUSINESS WIRE)--Revance to Participate in Upcoming Virtual Healthcare Conferences

2 months ago - Business Wire

Dublin, Feb. 24, 2021 (GLOBE NEWSWIRE) -- The "Facial Injectable Market - Forecasts from 2020 to 2025" report has been added to ResearchAndMarkets.com's offering. The facial injectable market is project...

Other stocks mentioned: AGN
2 months ago - GlobeNewsWire

NASHVILLE, Tenn.--(BUSINESS WIRE)--Revance Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

2 months ago - Business Wire

SAN DIEGO--(BUSINESS WIRE)--Ambrx Appoints Audit Executive Chris Nolet to Board of Directors

Other stocks mentioned: PTE, VIE
2 months ago - Business Wire

Revance Therapeutics Inc (NASDAQ: RVNC) has reported topline data from JUNIPER Phase 2 study evaluating DaxibotulinumtoxinA for Injection to treat adults with moderate to severe upper limb spasticity. I...

2 months ago - Benzinga

Shares of Revance Therapeutics (NASDAQ:RVNC) increased in after-market trading after the company reported Q4 results. Quarterly Results Earnings per share fell 25.25% year over year to ($1.24), which we...

2 months ago - Benzinga

NASHVILLE, Tenn.--(BUSINESS WIRE)--Revance Announces Positive Topline Phase 2 Data Supporting Advancement of DaxibotulinumtoxinA for Injection for the Treatment of ULS

2 months ago - Business Wire

NASHVILLE, Tenn.--(BUSINESS WIRE)--Revance Reports Fourth Quarter and Full Year 2020 Financial Results

2 months ago - Business Wire

NASHVILLE, Tenn.--(BUSINESS WIRE)--Revance Appoints Olivia C. Ware and Carey O'Connor Kolaja to Board of Directors

2 months ago - Business Wire

On Monday, February 22, Revance Therapeutics (NASDAQ:RVNC) will release its latest earnings report. Benzinga's outlook for Revance Therapeutics is included in the following report.

2 months ago - Benzinga

NASHVILLE, Tenn.--(BUSINESS WIRE)--Governor Lee, Commissioner Rolfe Announce Revance Therapeutics to Relocate Global Headquarters to Nashville

4 months ago - Business Wire

Revance (RVNC) announces a delay in the FDA decision on its BLA for DaxibotulinumtoxinA for Injection due to COVID-19.

5 months ago - Zacks Investment Research

Revance Therapeutics, Inc. (RVNC) CEO Mark Foley on Q3 2020 Results - Earnings Call Transcript

6 months ago - Seeking Alpha

Shares of Revance Therapeutics (NASDAQ:RVNC) decreased 8.62% in after-market trading after the company reported Q3 results. Quarterly Results Earnings per share were down 39.58% year over year to ($1.34...

6 months ago - Benzinga

Revance (RVNC) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

6 months ago - Zacks Investment Research

Revance Therapeutics shows improving price performance, earning an upgrade to its IBD Relative Strength Rating. The post Stocks Showing Market Leadership: Revance Therapeutics Earns 93 RS Rating appeare...

8 months ago - Investors Business Daily

Revance Therapeutics, Inc. (RVNC) CEO Mark Foley on Q2 2020 Results - Earnings Call Transcript

9 months ago - Seeking Alpha

Revance Therapeutics (RVNC) saw a big move last session, as its shares jumped nearly 6% on the day, amid huge volumes.

10 months ago - Zacks Investment Research

Revance Therapeutics, Inc. (RVNC) CEO Mark Foley on Q1 2020 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

As of late, it has definitely been a great time to be an investor in Revance Therapeutics.

1 year ago - Zacks Investment Research

Revance (RVNC) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

1 year ago - Zacks Investment Research

Investors need to pay close attention to Revance Therapeutics (RVNC) stock based on the movements in the options market lately.

1 year ago - Zacks Investment Research

Revance Therapeutics, Inc. (RVNC) CEO Mark Foley on Q4 2019 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

The company's frown line treatment moved closer to commercialization today.

1 year ago - The Motley Fool

As of late, it has definitely been a great time to be an investor in Revance Therapeutics.

1 year ago - Zacks Investment Research

Revance Therapeutics: A Robust Pick For 2020

1 year ago - Seeking Alpha

A new deal accelerates the company's shift to a commercial-stage biotech.

1 year ago - The Motley Fool

Revance Therapeutics: The Real Threat To Abbvie's Dividend

1 year ago - Seeking Alpha

Several companies raised capital on Wednesday.

Other stocks mentioned: DT, IMMU
1 year ago - The Motley Fool

The pricing of a secondary offering is to blame.

1 year ago - The Motley Fool

Revance Therapeutics, Inc. (RVNC) CEO Mark Foley on Q3 2019 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

Earlier this month, Revance Therapeutics Inc (NASDAQ: RVNC) named Mark Foley as its new CEO.

1 year ago - Benzinga

Possible merger and acquisition activity lifted one of these stocks.

Other stocks mentioned: HLT, VNET
1 year ago - The Motley Fool

Biotech Revance Therapeutics Inc. RVNC, +4.46% said Monday it has named Mark J. Foley as chief executive, replacing Dan Browne who has stepped down due to a misjudgment in handling an employee matter.

1 year ago - Market Watch

Revance's DAXI seems to have a longer duration of effect than botox and its current competitors.

1 year ago - Seeking Alpha

These 10 monster growth stocks to buy all offer exciting opportunities. There's the important information for investors to keep in mind.

Other stocks mentioned: AERI, AMZN, CRM, CXO, DBX, FANG, NTNX ...
1 year ago - InvestorPlace

Revance Therapeutics, Inc. (RVNC) CEO Daniel Browne on Q2 2019 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

Revance (RVNC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

1 year ago - Zacks Investment Research

Revance's share price has been battered over the past year.

1 year ago - Seeking Alpha

Revance Therapeutics (RVNC) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.

1 year ago - Zacks Investment Research

Revance Therapeutics, Inc. (RVNC) on Q1 2019 Results - Earnings Call Transcript

2 years ago - Seeking Alpha

About RVNC

Revance Therapeutics, Inc., a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead drug candidate is DaxibotulinumtoxinA for injection (DAXI), which has completed phase III clinical trials for the treatment of glabellar (frown) lines and cervical dystonia; is in phase II clinical trials to treat upper facial lines, moderate or severe dynamic forehead lines, and moderate or severe late... [Read more...]

Industry
Biotechnology
IPO Date
Feb 6, 2014
CEO
Mark Foley
Employees
470
Stock Exchange
NASDAQ
Ticker Symbol
RVNC
Full Company Profile

Financial Performance

In 2020, RVNC's revenue was $15.33 million, an increase of 3,610.65% compared to the previous year's $413,000. Losses were -$282.09 million, 76.9% more than in 2019.

Financial Statements

Analyst Forecasts

According to 11 analysts, the average rating for RVNC stock is "Buy." The 12-month stock price forecast is 38.20, which is an increase of 39.26% from the latest price.

Price Target
$38.20
(39.26% upside)
Analyst Consensus: Buy